GET DAILY SIGNALSMIRA Pharmaceuticals (NASDAQ: MIRA): Assessing the Road to $5.75 and a Potential +780% Upside
Key Takeaways
- The $5.75 central target represents the arithmetic mean of the two current analyst price targets: Maxim Group’s $3.50 and Rodman & Renshaw’s $8.00.
- From a recent price near $0.65, reaching $5.75 would imply a gain of roughly 780%, a substantial move even for a speculative biotech name.
- Analyst targets range widely from $3.50 to $8.00, underscoring uncertainty around early-stage pipeline progress and financing needs.
- The clearest potential support comes from clinical advancement of Ketamir-2, with the first subjects recently enrolled in its Phase 1 trial.
- Key risks include the lack of revenue, ongoing cash burn, limited cash position, trading near 52-week lows, and very thin analyst coverage.
Analyst Price Targets and Consensus View
Coverage of MIRA remains limited, so the “consensus” deserves careful interpretation. Only two current, attributed price targets stand out. Maxim Group analyst Jason McCarthy started coverage with a Buy rating and $3.50 target in September 2026, then reiterated both in late October 2026. Rodman & Renshaw analyst Mike King initiated with a Buy rating and $8.00 target in January 2026. An older $17 target from 2024 was set aside as outdated relative to the current price and capital structure.
The simple average of the two active targets lands at $5.75, with the range spanning $3.50 to $8.00. That spread highlights meaningful disagreement even among bullish analysts, which is common for pre-revenue companies where one clinical or financing event can shift the outlook sharply. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. MarketBeat and similar services may show a single $3.50 figure or a more cautious blended view, but the attributable data points remain these two Buy-rated targets. The $5.75 level is best viewed as a rough midpoint of optimistic scenarios rather than a precise prediction.
Current Market Position and Path Toward the Target
MIRA has traded in a 52-week range of roughly $0.51 to $1.69 and recently changed hands near $0.65, close to the lower end, with a market capitalization around $27 million. A move to $5.75 would represent upside of approximately 780%—a very large advance that would essentially require the market to re-rate the company from a sub-$30 million microcap into a materially higher valuation.
The path, if any, would likely run through de-risking clinical milestones rather than current financials. MIRA generates no meaningful revenue and reported a trailing twelve-month net loss with negative EPS and a cash balance of only a few million dollars in its most recent quarter. As a pre-revenue developer, its valuation is driven almost entirely by expectations for its drug candidates.
What Could Support a Move Toward the Target
The clearest catalyst is clinical execution on Ketamir-2. The company announced in May 2026 that the first subjects had been enrolled in its Phase 1 trial for neuropathic pain, and Ketamir-2 is described as having completed an earlier Phase 1 trial. Favorable safety and early efficacy data, along with continued advancement of MIRA-55 and the preclinical SKNY-1 program, could strengthen the bull case. Positive analyst revisions, additional coverage, and successful capital raises at higher valuations would also help. Small-cap biotech sentiment can shift quickly and amplify moves in either direction.
What Could Prevent the Target From Being Reached
Several factors weigh against the target. The company is pre-revenue, posts significant losses, and holds limited cash, creating ongoing dilution risk. Clinical-stage programs frequently face delays or setbacks, and any issue in Ketamir-2’s Phase 1 trial could sharply revalue the stock. The shares trade near their 52-week low, reflecting weak sentiment, and the analyst base is extremely thin. High volatility and a wide bid-ask spread add practical hurdles.
Technical Levels and Market Structure
From a technical standpoint, MIRA sits in a long-term downtrend within its 52-week range. The $0.51 area marks major support and the prior low, while $1.00 and the $1.69 high serve as overhead resistance. The stock’s inability to hold above $1.00 points to persistent selling pressure. Given the penny-stock structure, technical levels are less reliable than clinical news as price drivers.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly twelve-month horizon. For MIRA, the most important items to watch are Ketamir-2 Phase 1 data readouts, enrollment and safety updates, regulatory milestones, and financing activity. Quarterly updates on cash runway and progress on MIRA-55 and SKNY-1 also matter, along with any changes in analyst views.
Using AI Tools for Ongoing Monitoring
In my own research, I often turn to Tickeron’s AI Daily Buy/Sell Signals to help track momentum shifts in volatile microcaps like this one. The tool applies artificial intelligence to monitor market conditions and technical behavior across thousands of stocks, which can complement clinical and fundamental analysis without replacing it.
Final Assessment
The $5.75 central target, derived as the mean of two Buy-rated analyst targets of $3.50 and $8.00, sits far above MIRA’s recent price near $0.65, implying an exceptionally large move of roughly 780%. The bullish case rests on successful advancement of Ketamir-2 and the broader neuroscience pipeline, while the bearish case centers on limited cash, no revenue, recent trading near 52-week lows, and a very thin, widely divergent analyst base. The target range itself underscores the extreme uncertainty. Whether the shares can bridge that gap will depend less on current financials than on clinical data, financing terms, and investor sentiment toward early-stage biotech. No outcome is guaranteed, and the target should be read as an optimistic midpoint, not a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MIRA's RSI Indicator climbs out of oversold territory
The RSI Oscillator for MIRA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 21 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MIRA as a result. In 52 of 60 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for MIRA just turned positive on November 06, 2026. Looking at past instances where MIRA's MACD turned positive, the stock continued to rise in 24 of 29 cases over the following month. The odds of a continued upward trend are 83%.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRA advanced for three days, in 103 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
MIRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for MIRA crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for MIRA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.937) is normal, around the industry mean (-1.421). P/E Ratio (-0.468) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. MIRA's P/S Ratio (0.000) is slightly lower than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. MIRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsMajor
Advertisement